CONTENIDO

Transient increment of HTLV-2 proviral load in HIV-1- coinfected patients during treatment intensification with raltegravir

09/01/2014

J Clin Virol. 2014, Mar;59(3):204-7.

Abstract

Background

Numerous studies have analyzed the effects of raltegravir intensification on HIV-1 viral replication in infected individuals receiving suppressive combined antiretroviral treatment (cART). Nevertheless, there are only two studies on the effect of raltegravir in HTLV-1 infection, and none in HTLV-2.

 

Objective

To study the effect of raltegravir on HTLV-2 infection in HIV-1-co-infected individuals.

 

Study design

This retrospective longitudinal study included four HTLV-2-HIV-1-co-infected individuals who received raltegravir-based cART during 48 weeks and 11 HTLV-2-HIV-1-co-infected individuals under cART without raltegravir during 48 weeks. HTLV-2 proviral load, CD4 and CD8 count and frequency were analyzed.

 

Results

HTLV-2 proviral load significantly increased at week 24 compared to baseline among all the patients who received raltegravir (p = 0.003), while no significant increases were found in the control group. No significant variation in either CD8 or CD4 counts was found during the follow up in both groups.

 

Conclusions

Raltegravir induced a transient increment on total HTLV-2 DNA proviral load in HTLV-2/HIV-1-coinfected individuals on suppressive cART after 24 weeks.

 

Read abstract online

Abad-Fernández M, Cabrera C, García E, Vallejo A.

See author affiliations

Grupos de IrsiCaixa vinculados: Virología Tisular (VITI)